Former MADD CEO Debbie Weir Joins Cancer Vaccine Coalition to Accelerate Immunotherapy Revolution

In a powerful shift from public safety to public health, Debbie Weir, the former CEO of Mothers Against Drunk Driving (MADD), has joined the Cancer Vaccine Coalition (CVC) as Chief Impact Officer. Teaming up with breast cancer survivor and former NBC correspondent Kristen Dahlgren, Weir is now championing the next frontier of cancer care: therapeutic cancer vaccines.

A Shift Toward Immune-Based Cancer Treatments

Founded in 2024, the Cancer Vaccine Coalition is the only national nonprofit in the U.S. dedicated to funding clinical trials for cancer vaccines—an emerging class of treatments that aim to train the immune system to detect and destroy cancer cells. As traditional treatments often carry severe side effects, immune-activating therapies promise a less toxic, more targeted solution.

Weir’s appointment reflects growing urgency as the U.S. faces over 2 million cancer diagnoses annually, with 18.6 million survivors at risk of recurrence. Cancer vaccines represent a paradigm shift in cancer treatment and prevention.

Operational Details and Leadership Vision

In her new role, Weir will lead national strategy, stakeholder engagement, and impact initiatives from her base in Washington, D.C. Known for her ability to catalyze cultural transformation, she previously led efforts at MADD that resulted in a 50% reduction in drunk driving deaths.

Weir also served as Chief Mission Officer at Everytown for Gun Safety and most recently as CEO of the Cancer Support Community, supporting psychosocial services across 175+ locations in North America.

Her leadership brings a bold vision: to fast-track vaccine development by bridging research, advocacy, and public support.

Economic and Scientific Impact

Since its inception, CVC has raised over $2 million in philanthropic funds. It collaborates with top-tier institutions including MD Anderson, Dana-Farber Cancer Institute, Cleveland Clinic, Memorial Sloan Kettering, and Penn Medicine. These alliances are fueling progress in clinical trials, pushing cancer vaccines closer to FDA approval and mainstream deployment.

Kristen Dahlgren emphasized, “**Other countries are moving fast on cancer vaccine development—**we can’t afford to fall behind.”

Building a Cancer-Free Future

This leadership transition marks a milestone moment for the cancer immunotherapy movement. CVC is not only advancing the science of cancer vaccines but also creating a national platform for public involvement, funding, and education. By aligning nonprofit leadership with survivor advocacy and world-class research, the coalition is poised to change the trajectory of cancer treatment in America.